Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Alkermes plc - Ordinary Shares
(NQ:
ALKS
)
49.67
+0.14 (+0.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alkermes plc - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Alkermes Q2 Earnings Call Highlights
↗
July 28, 2026
Alkermes (NASDAQ:ALKS) reported second-quarter 2026 revenue of $496 million, supported by growth across its proprietary product portfolio and the first full-quarter contribution from LUMRYZ following...
Via
MarketBeat
Topics
Earnings
Alkermes (NASDAQ:ALKS) Reports Quality Earnings Beat but Stock Falls on Lack of Guidance
↗
July 28, 2026
Via
Chartmill
Topics
Earnings
Alkermes plc Reports Second Quarter 2026 Financial Results
July 28, 2026
From
Alkermes plc
Via
Business Wire
Alkermes to Report Second Quarter Financial Results on July 28, 2026
July 14, 2026
From
Alkermes plc
Via
Business Wire
Alkermes plc (NASDAQ:ALKS) Reports Mixed Q1 Results, Beats Revenue Forecasts but Posts Wider Than Expected Loss
↗
May 05, 2026
Via
Chartmill
Alkermes Plc (NASDAQ:ALKS) Shows Strong Technical Setup with High Breakout Potential
↗
April 29, 2026
Via
Chartmill
Alkermes PLC (NASDAQ:ALKS) Reports Strong Q4 Earnings Beat Amid Muted Market Reaction
↗
February 25, 2026
Via
Chartmill
Topics
Earnings
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
July 13, 2026
From
Alkermes plc
Via
Business Wire
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
June 17, 2026
From
Alkermes plc
Via
Business Wire
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
June 15, 2026
From
Alkermes plc
Via
Business Wire
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears
↗
June 10, 2026
Alkermes (NASDAQ:ALKS) executives said the company is entering a period of heightened execution as it advances its orexin agonist program into late-stage development, integrates Avadel and prepares for...
Via
MarketBeat
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
June 04, 2026
From
Alkermes plc
Via
Business Wire
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 03, 2026
From
Alkermes plc
Via
Business Wire
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
May 26, 2026
From
Alkermes plc
Via
Business Wire
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
May 21, 2026
From
Alkermes plc
Via
Business Wire
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
May 12, 2026
From
Alkermes plc
Via
Business Wire
Alkermes (ALKS) Q1 2026 Earnings Transcript
↗
May 05, 2026
Alkermes (ALKS) Q1 2026 Earnings Transcript
Via
The Motley Fool
Alkermes plc Reports First Quarter 2026 Financial Results
May 05, 2026
From
Alkermes plc
Via
Business Wire
Alkermes to Report First Quarter Financial Results on May 5, 2026
April 21, 2026
From
Alkermes plc
Via
Business Wire
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
April 16, 2026
From
Alkermes plc
Via
Business Wire
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
April 14, 2026
From
Alkermes plc
Via
Business Wire
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
April 06, 2026
On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total...
Via
MarketMinute
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
April 01, 2026
From
Alkermes plc
Via
Business Wire
The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals
March 31, 2026
Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals...
Via
Finterra
Topics
Economy
Initial Public Offering
Intellectual Property
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
March 12, 2026
From
Alkermes plc
Via
Business Wire
Alkermes to Present at the Stifel 2026 Virtual CNS Forum
March 10, 2026
From
Alkermes plc
Via
Business Wire
Alkermes (ALKS) Q4 2025 Earnings Call Transcript
↗
February 25, 2026
Alkermes (ALKS) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
February 25, 2026
From
Alkermes plc
Via
Business Wire
Alkermes plc Announces CEO Succession Plan
February 25, 2026
From
Alkermes plc
Via
Business Wire
Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
From
Alkermes plc
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
